After spending several months in direct conversations with food manufacturers evaluating animal-free dairy ingredients, the questions have settled into a predictable pattern. Not because manufacturers are uncreative, but because the questions that actually determine whether an ingredient works in their operation converge on six core issues. This is what they ask.
1. Is this chemically the same protein as what I am already using?
This is the first question and the most important one. Formulators do not want a protein that is similar to bovine casein or similar to native whey fractions. They want to know whether the amino acid sequence, molecular weight, and post-translational modification pattern are identical to the native bovine protein, or whether they are dealing with a structurally different molecule that happens to have similar bulk properties.
The reason this matters so much is formulation IP and regulatory history. A food manufacturer who has spent 18 months developing a product formula optimized around the functional behavior of native bovine beta-Casein does not want to restart that work because the substitute protein has a slightly different phosphorylation pattern or a modified C-terminus that changes its behavior in their specific processing conditions. Chemical identity is the precondition for functional equivalence.
For our BC-1 fraction, the answer is yes: the amino acid sequence is identical to native bovine beta-Casein, molecular weight by mass spectrometry confirms 23.6 kDa consistent with the native reference, and our downstream processing is designed to preserve the native protein structure rather than modify it. We provide the mass spec data and HPLC purity profiles with every sample.
2. What is the batch-to-batch consistency I should expect?
Protein purity on a spec sheet is a point estimate. What manufacturers want to know is the distribution around that estimate: what is the range, what is the standard deviation, and how many consecutive batches do they have data from. A claimed 94% HPLC purity means very different things if it comes from one batch versus 12 consecutive batches.
We report our batch-to-batch consistency as CV across 12 sequential pilot production runs: 2.7% for protein purity. We give procurement teams the full run log, not just the summary statistics. Procurement teams at ingredients-buying organizations have seen enough single-point spec sheets to know that they do not provide meaningful assurance of production stability.
The follow-up question that comes with this one is usually: what happens when something goes wrong in your process? This is a fair question. We have had batches where CO2 control drifted, where media component lot variation affected yield, and where we had to abort a batch partway through for contamination reasons. Our answer is that we have a batch disposition protocol, we discard batches that fall outside specification, and we document what went wrong and what we changed. We show manufacturers this documentation on request. The ability to say clearly what a bad batch looks like and confirm that it does not reach them is part of the quality conversation.
3. What is the regulatory status, and will I be able to use this in my products?
Formulators cannot use an ingredient that has not cleared the regulatory pathway in their market. The question is blunt and it should be. We are engaged in pre-submission discussions with Health Canada under the Novel Food Regulations. We do not have a clearance, and we do not represent that we do. We provide formulation partners with the full technical documentation package that supports a regulatory filing, and we are transparent about where we are in the process and what the realistic timeline looks like.
What we tell manufacturers is: formulation work and regulatory evaluation can proceed in parallel. Running a technical evaluation on an ingredient before its regulatory clearance is in place is standard practice in the food industry for ingredients in active regulatory review. The commercial launch decision comes later, when clearance is confirmed. We do not ask anyone to commit to commercial scale before the regulatory situation is resolved.
4. What does the allergen picture look like?
Dairy is a top allergen in Canada, the EU, and the US, with mandatory declaration requirements across all three jurisdictions. This creates a complicated question for animal-free dairy proteins: if you are producing a protein that is chemically identical to bovine casein, does it carry the same allergenicity risk profile as bovine casein?
The honest answer based on current scientific understanding is yes. The allergenicity of bovine casein is associated with specific epitopes in its primary amino acid sequence. If BC-1 has the same primary sequence, it would be expected to be allergenic to individuals sensitized to bovine milk proteins. We declare this clearly in our technical documentation and we do not attempt to market our ingredients as hypoallergenic. Manufacturers using them in food products will need to declare the presence of milk protein, and the labeling considerations that apply to conventional dairy ingredients apply to ours.
This is an area where we expect more clarity to emerge from allergenicity testing as the category develops, but the precautionary position is that cell-cultured bovine dairy proteins carry the same allergen declaration requirements as their conventional counterparts.
5. What are the handling and storage requirements?
BC-1 is supplied as a lyophilized powder. Shelf life at recommended storage conditions (below 25 degrees Celsius, low humidity, protected from light) is 18 months based on accelerated stability data. Reconstitution protocol, minimum solubility conditions, and sensitivity to pH and ionic strength are documented in the technical handling guide that accompanies each sample.
The question behind this question is usually about whether the ingredient will behave unexpectedly in a plant with existing production lines calibrated for conventional dairy proteins. In most cases, handling requirements are comparable to sodium caseinate or casein concentrate in conventional use. We recommend a reconstitution trial before any pilot production run to confirm solubility and dispersion behavior under the manufacturer's specific water quality and temperature conditions.
6. What quantities are realistically available and on what timeline?
This is the question that separates curiosity from procurement intent. Our current capacity is pilot-scale: we can supply quantities appropriate for formulation trials, pilot-scale production runs, and regulatory submission packages. We are not in a position to supply ingredient quantities for commercial-scale production today, and we do not pretend otherwise.
Manufacturers who are evaluating for future commercial supply need to understand the production development trajectory. We are scaling our production capability and working toward larger bioreactor configurations. The timeline to commercial-scale supply is a function of production engineering progress and regulatory clearance timing. Both are in progress.
What we offer now is a genuine technical evaluation pathway: sample quantities with full specification documentation, a formulation consultation with our protein science team, and a development partnership framework for manufacturers who want to be involved in specification development for their specific application. The early-access program is not a marketing funnel, it is a way to work through the formulation questions with manufacturers who will eventually become ingredient buyers, while both sides learn what the ingredient can and cannot do.